The Board of Directors of Instadose Pharma Corp., a Nevada corporation, announced that effective January 14, 2022, they have accepted the planned resignation of Grant F. Sanders as Chairman and CEO of Instadose US and as Chairman of its wholly owned Canadian subsidiary. Mr. Sanders will not hold any officer or director positions at Instadose US or Instadose Canada following his resignation.
Mr. Sanders had committed to lead Instadose Canada through its transition to a publicly traded US company (Instadose US), as outlined in the Final Order of the Supreme Court of British Columbia approving the plan of arrangement between Instadose US and Instadose Canada. After completion of the share exchange on December 31, 2021, which was the exchange of shares from Instadose Canada to Instadose US, and the first record setting international Cannabis shipment, Mr. Sanders has paved the road to success for the Instadose US business model. “I feel confident that the new management team and corporate structure is in excellent position to execute on my vision of Instadose US becoming the largest global distribution platform for medicinal cannabis,” stated Mr. Sanders.
During a 30-day transition period, Mr. Sanders will continue to support Instadose US and its wholly owned subsidiary (Instadose Canada) with his in-depth knowledge of this global cannabis distribution platform.
Alex Wylie will assume the role of interim Chairman of Instadose US, and interim CEO of Instadose US and Instadose Canada Mr. Wylie will continue in his role as CFO of Instadose US and Instadose Canada. Instadose US’ Board of Directors will initiate a process to find a permanent Chairman and CEO of Instadose US. Alex Wylie will be a potential candidate for the role of CEO and/or Chairman.
Ed Borkowski has decided not to accept the position of CEO of Instadose Canada and instead agreed to assume the position as Vice Chairman of Instadose Canada. He will advise and guide the organization as it continues its transition into the US public markets.
About Instadose US
Instadose US is establishing a large commercial outdoor growing, cultivation, production and global distribution platform for medicinal cannabis and cannabinoid oil (the “Global Distribution Platform“). Instadose US endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace capable of providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low-cost supplies of high-quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient. Instadose US’s Global Distribution Platform spans five (5) world continents to date, including Africa, Europe, Asia, South America, and North America. Within each continent, Instadose US is establishing operational subsidiaries and joint venture partnerships to secure access to government-issued licenses and permits in countries including The Democratic Republic of the Congo, the Republic of North Macedonia, the Portuguese Republic, the Republic of India, Colombia, Mexico, and Canada, each seeking to increase their level of participation within the global medicinal cannabis industry.
For more information, please visit us at: www.instadosepharma.com
